Top

Journal of Orthopaedic Science

Published in:

01-11-2012 | Original Article

Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up

Authors: Naoki Takeda, Kazuo Isu, Hiroaki Hiraga, Nobuo Shinohara, Akio Minami, Hajime Kamata

Published in: Journal of Orthopaedic Science | Issue 6/2012

Abstract

Background

Renal cell carcinoma (RCC) is thought to respond unreliably to radiotherapy (RT). Zoledronic acid significantly reduces the risk of skeletal complications. This study investigated whether RT with zoledronic acid prolonged the time to bone-lesion progression in comparison with RT alone.

Method

Twenty-seven patients (34 lesions) with bone metastases secondary to RCC undergoing treatment with RT with or without zoledronic acid were retrospectively evaluated at two institutions between 1999 and 2009. Twelve patients were treated with RT alone from 1999 to 2008 (RT group). Fifteen patients were treated with RT and zoledronic acid from 2006 to 2009 (RT + Z group). The time to skeletal-related events and pain progression were assessed from patients’ medical records.

Results

The median (range) follow-up was 26 (3–75) and 24 (3–55) months in the RT and RT + Z groups, respectively. Three patients (three lesions) in the RT + Z group had skeletal-related events (SREs). In contrast, six patients (eight lesions) in the RT group had SREs. SREs comprised pathological fractures in five, additional surgeries in three, spinal cord or cauda equine compression in two, and repeat RT in one. There was a significant difference in SRE-free survival time and duration of site-specific pain response between groups.

Conclusions

RT combined with zoledronic acid significantly prolonged SRE-free survival and duration of pain response compared with RT alone in the treatment of osseous metastases from RCC.

Tobisu K, Kakizoe T, Takai K, Tanaka Y. Prognosis in renal cell carcinoma: analysis of clinical course following nephrectomy. Jpn J Clin Oncol. 1989;19:142–8.PubMed

Toyada Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007;52:163–9.CrossRef

Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patients survival after for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007;89:1794–801.PubMedCrossRef

Kume H, Kakutani S, yamada Y, Shinohara M, Tominaga T, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Homma Y. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J Urol. 2011;185:1611–4.PubMedCrossRef

Fertil B, Malaise E. Intrinsic radiosensitivity of human cell lines is correlated with radio responsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985;11:1699–707.PubMedCrossRef

Wilson D, Hiller L, Gray L, Grainger M, Stirling A, James N. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol. 2003;15:400–7.CrossRef

Lee J, Hodgson D, Chow E, Bezjak A, Catton P, Tsuji D, O’Brien M, Danjoux C, Hayter C, Warde P, Gospodarowicz MK. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer. 2005;104:1894–900.PubMedCrossRef

DiBiase SJ, Valicent RK, Schultz D, Xie Y, Gomella LG, Corn BW. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol. 1997;158:746–9.PubMedCrossRef

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377–87.PubMed

10.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735–44.PubMedCrossRef

11.

Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 15;21(16):3150–7.

12.

Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases. Cancer. 2008;113:1438–45.PubMedCrossRef

13.

Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962–9.PubMedCrossRef

14.

Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int. 2009;103:620–4.PubMedCrossRef

15.

Arrington SA, Damron TA, Mann KA, Allen WJ. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and micro architecture in a mouse model of tumor-induced osteolysis. J Surg Oncol. 2008;97:284–90.PubMedCrossRef

16.

Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AM, Ribatti D, Dammacco F, Vacca A. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther. 2007;6:3256–62.PubMedCrossRef

17.

Yoneda Y, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen A, Taguchi A, Toyosawa S, Nagata T, Urade M. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28:365–83.PubMedCrossRef

Title: Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up
Authors: Naoki Takeda
Kazuo Isu
Hiroaki Hiraga
Nobuo Shinohara
Akio Minami
Hajime Kamata
Publication date: 01-11-2012
Publisher: Springer Japan
Published in: Journal of Orthopaedic Science / Issue 6/2012
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-012-0294-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up

Abstract

Background

Method

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

Treatment for primary spinal atypical teratoid/rhabdoid tumor

Medium-term result of Elite Plus hip arthroplasty: the second modular evolution of the original Charnley low-friction arthroplasty

Normative score and cut-off value of the Neck Disability Index

Sagittal lumbar and pelvic alignment in the standing and sitting positions

Remodeling of angulation deformities in diaphyseal femoral fracture in children

Extensor digiti minimi transfer for thumb extension in a patient with hypoplastic thumb extensor tendons and absent extensor indicis proprius